NICARDIPINE HYDROCHLORIDE

Post-LOE

Hikma

ANDAINJECTIONINJECTABLE

Approved

Dec 2009

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

NICARDIPINE HYDROCHLORIDE by Hikma is concentrations. Approved for not desirable. First approved in 2009.

Drug data last refreshed 19h ago

Mechanism of Action

concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine are more selective to vascular smooth muscle than cardiac muscle. In animal…

Indications (1)

not desirable

Company

Worked on NICARDIPINE HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.